Co-Authors
This is a "connection" page, showing publications co-authored by Riyazuddin Shaik and Hamad Al Romaihi.
Connection Strength
0.650
-
Pfizer-BioNTech mRNA BNT162b2 Covid-19 vaccine protection against variants of concern after one versus two doses. J Travel Med. 2021 10 11; 28(7).
Score: 0.061
-
Assessment of the Risk of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Reinfection in an Intense Reexposure Setting. Clin Infect Dis. 2021 10 05; 73(7):e1830-e1840.
Score: 0.061
-
mRNA-1273 COVID-19 vaccine effectiveness against the B.1.1.7 and B.1.351 variants and severe COVID-19 disease in Qatar. Nat Med. 2021 09; 27(9):1614-1621.
Score: 0.060
-
Analytic comparison between three high-throughput commercial SARS-CoV-2 antibody assays reveals minor discrepancies in a high-incidence population. Sci Rep. 2021 06 04; 11(1):11837.
Score: 0.059
-
SARS-CoV-2 seroprevalence in the urban population of Qatar: An analysis of antibody testing on a sample of 112,941 individuals. iScience. 2021 Jun 25; 24(6):102646.
Score: 0.059
-
SARS-CoV-2 Infection Is at Herd Immunity in the Majority Segment of the Population of Qatar. Open Forum Infect Dis. 2021 Aug; 8(8):ofab221.
Score: 0.059
-
Herd Immunity against Severe Acute Respiratory Syndrome Coronavirus 2 Infection in 10 Communities, Qatar. Emerg Infect Dis. 2021 05; 27(5):1343-1352.
Score: 0.059
-
SARS-CoV-2 antibody-positivity protects against reinfection for at least seven months with 95% efficacy. EClinicalMedicine. 2021 May; 35:100861.
Score: 0.059
-
Epidemiological impact of prioritising SARS-CoV-2 vaccination by antibody status: mathematical modelling analyses. BMJ Innov. 2021 Apr; 7(2):327-336.
Score: 0.059
-
Mathematical modeling of the SARS-CoV-2 epidemic in Qatar and its impact on the national response to COVID-19. J Glob Health. 2021 Jan 16; 11:05005.
Score: 0.058
-
Two prolonged viremic SARS-CoV-2 infections with conserved viral genome for two months. Infect Genet Evol. 2021 03; 88:104684.
Score: 0.058